TY - JOUR T1 - Rivaroxaban plus aspirin for secondary prevention JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 124 LP - 124 DO - 10.1136/dtb.2017.10.0547 VL - 55 IS - 11 A2 - , Y1 - 2017/11/01 UR - http://dtb.bmj.com/content/55/11/124.abstract N2 - Aspirin is well established in the secondary prevention of cardiovascular disease. In a meta-analysis of 16 secondary prevention trials (17,000 participants), aspirin has been shown to reduce serious vascular events (6.7% vs 8.2% per year, p<0.0001) with reductions in total stroke (2.08% vs 2.54% per year, p=0.002) and in coronary events (4.3% vs. 5.3% per year, p<0.0001).1 A trial has assessed whether rivaroxaban alone or in combination with aspirin is more … ER -